Tarsus Price To Operating Cash Flows Ratio from 2010 to 2024
| TARS Stock | USD 48.24 1.84 3.97% |
Price To Operating Cash Flows Ratio | First Reported 2010-12-31 | Previous Quarter (5.06) | Current Value (5.32) | Quarterly Volatility 56.60615483 |
Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 6.8 M or Depreciation And Amortization of 529.3 K, as well as many indicators such as Price To Sales Ratio of 35.81, Dividend Yield of 0.0 or PTB Ratio of 3.17. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.
Tarsus | Price To Operating Cash Flows Ratio |
Latest Tarsus Pharmaceuticals' Price To Operating Cash Flows Ratio Growth Pattern
Below is the plot of the Price To Operating Cash Flows Ratio of Tarsus Pharmaceuticals over the last few years. It is Tarsus Pharmaceuticals' Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tarsus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Price To Operating Cash Flows Ratio | 10 Years Trend |
|
Price To Operating Cash Flows Ratio |
| Timeline |
Tarsus Price To Operating Cash Flows Ratio Regression Statistics
| Arithmetic Mean | (47.62) | |
| Geometric Mean | 45.56 | |
| Coefficient Of Variation | (118.86) | |
| Mean Deviation | 40.54 | |
| Median | (74.55) | |
| Standard Deviation | 56.61 | |
| Sample Variance | 3,204 | |
| Range | 233 | |
| R-Value | 0.58 | |
| Mean Square Error | 2,280 | |
| R-Squared | 0.34 | |
| Significance | 0.02 | |
| Slope | 7.37 | |
| Total Sum of Squares | 44,860 |
Tarsus Price To Operating Cash Flows Ratio History
About Tarsus Pharmaceuticals Financial Statements
Tarsus Pharmaceuticals shareholders use historical fundamental indicators, such as Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Although Tarsus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tarsus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tarsus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Operating Cash Flows Ratio | (5.06) | (5.32) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.